Treatment Access, Policy, and Emerging Therapies
Access to adult ADHD treatment under scrutiny – RACGP (Www1.Racgp.Au)
Summary: A recent Four Corners investigation scrutinizes huge variations in adult ADHD prescription rates, raising concerns about misdiagnosis and missed diagnoses. This matters for Alzheimer’s Disease and Frontal Temporal Dementia because it gives a concrete current signal to track: A recent Four Corners investigation scrutinizes huge variations in adult ADHD prescription rates, raising concerns about misdiagnosis and missed diagnoses.
Why it matters: This matters for Alzheimer’s Disease and Frontal Temporal Dementia because it gives a concrete current signal to track: A recent Four Corners investigation scrutinizes huge variations in adult ADHD prescription rates, raising concerns about misdiagnosis and missed diagnoses.
Context: A recent Four Corners investigation scrutinizes huge variations in adult ADHD prescription rates, raising concerns about misdiagnosis and missed diagnoses. This matters for Alzheimer’s Disease and Frontal Temporal Dementia because it gives a concrete current signal to track: A recent Four Corners investigation scrutinizes huge variations in adult ADHD prescription rates, raising concerns about misdiagnosis and missed diagnoses.
"A recent Four Corners investigation scrutinizes huge variations in adult ADHD prescription rates, raising concerns about misdiagnosis and missed diagnoses." — WWW1.RACGP.AU
Commentary: The immediate implication is operational rather than speculative: watch how this changes budgets, workflows, or risk assumptions over the next cycle.
Date: April 18, 2026 12:00 AM ET
URL: https://www1.racgp.org.au/newsgp/professional/access-to-adult-adhd-treatment-under-scrutiny
AI Sentiment Score: Negative (66%)
AI Credibility Score: 7.0/10 — Medium
Scores and text generated by AI analysis of the source article indicated.Is Cannabis Effective for ADHD? (Businessofcannabis)
Summary: The evidence base for cannabis as an ADHD treatment is remarkably thin despite widespread patient conviction and prescribing. A single underpowered RCT, neuroimaging data suggesting chronic use may blunt dopamine production, and a preponderance of uncontrolled patient reports constitute the entire substantive literature. This creates a significant gap between clinical evidence and real-world practice in legal markets.
Why it matters: For clinicians, patients, and regulators, the disconnect between high demand and scant evidence creates clinical risk, complicates policy, and leaves a vulnerable population navigating a heavily skewed online information environment.
Context: ADHD patients report high rates of self-medication with cannabis, driven by dissatisfaction with stimulant side effects and strong anecdotal reports of benefit, particularly for inattention and emotional dysregulation.
"ADHD is one of the most commonly reported reasons people seek medical cannabis prescriptions in legalised markets, yet the controlled evidence base for this indication is severely lacking, to the point of being almost non-existent." — BUSINESSOFCANNABIS
Commentary: The situation exemplifies a broader pattern in medical cannabis: clinical practice outpaces evidence, driven by patient demand and biological plausibility. This creates a regulatory and ethical dilemma. Prescribing without robust data risks patient harm, particularly regarding dependency in a population already at elevated risk for substance use disorder. Conversely, dismissing patient-reported benefits outright ignores the real limitations of first-line treatments. The field urgently needs pragmatic trials using THC-dominant products in treatment-resistant, comorbid populations over longer durations to assess both efficacy and dependency risk.
Date: April 16, 2026 12:00 AM ET
URL: https://businessofcannabis.com/is-cannabis-effective-for-adhd/
AI Sentiment Score: Negative (54%)
AI Credibility Score: 7.0/10 — Medium
Scores and text generated by AI analysis of the source article indicated.Stanford Psychiatry’s Corey Keller Awarded Grant to Research Biomarkers to Improve Efficacy of rTMS for Treatment-Resistant Depression (Med.Stanford.Edu)
Summary: Stanford Psychiatry’s Corey Keller receives NIMH funding to investigate EEG-based biomarkers for personalizing rTMS treatment in treatment-resistant depression. The project focuses on early local TMS-evoked potentials (EL-TEPs) to measure prefrontal excitability, aiming to tailor pulse count and intensity to individual neural responses. This seeks to address the current limitation where only about half of patients show sustained clinical improvement from the FDA-cleared therapy.
Why it matters: This research directly targets the operational inefficiency and high non-response rate in a major neuromodulation therapy, with implications for treatment protocols, payer models, and the clinical translation of precision psychiatry.
Context: rTMS is a cornerstone non-pharmacological intervention for treatment-resistant depression, but its application remains largely standardized. The field is moving toward biomarker-guided personalization to improve outcomes and justify cost, paralleling trends in oncology and neurology.
"Stanford Psychiatry’s Corey Keller Awarded Grant to Research Biomarkers to Improve Efficacy of rTMS for Treatment-Resistant Depression April 2026 We are pleased to announce that Stanford Psychiatry’s Corey Keller, Associate Professor of." — MED.STANFORD.EDU
Commentary: Keller’s work represents a concrete step toward operationalizing precision neuromodulation, shifting rTMS from a population-level protocol to a patient-specific intervention. Success would pressure clinical practices to adopt biomarker-guided dosing, potentially reshaping reimbursement models around demonstrated neural target engagement rather than session count. It also advances a mechanistic framework for depression, treating clinical response as a measurable circuit property rather than a behavioral symptom alone.
Date: April 15, 2026 12:00 AM ET
URL: https://med.stanford.edu/psychiatry/news/new-funding-announcement/biomarkers.html
AI Sentiment Score: Negative (66%)
AI Credibility Score: 7.0/10 — Medium
Scores and text generated by AI analysis of the source article indicated.April IACC Comments – 2026 (Autisticadvocacy)
Summary: The Autistic Self Advocacy Network has submitted comments to the Interagency Autism Coordinating Committee (IACC) ahead of its first public meeting under the current administration. ASAN expresses concern over diminished autistic representation on the committee, noting only three of 21 public members are autistic, down from seven previously. It raises alarms about several new public members’ histories of endorsing non-evidence-based medical interventions and discredited positions on vaccines. The organization calls for a renewed focus on research that supports living autistic people, prioritizing science-backed evidence and ethical practices.
Why it matters: The composition and priorities of the IACC directly influence federal autism research funding and policy, with immediate consequences for resource allocation, scientific legitimacy, and community trust.
Context: The IACC, mandated by the Autism CARES Act to coordinate federal efforts and include autistic voices, had failed to meet statutory requirements in 2025, leading to policy development without public input.
"These comments are available as a PDF with citations here. The Autistic Self Advocacy Network appreciates the opportunity to submit comments for the March 19, 2026, Interagency Autism Coordinating Committee (IACC) meeting." — AUTISTICADVOCACY
Commentary: The shift in IACC membership signals a potential institutional pivot toward causation-focused and non-evidence-based research, risking a diversion of federal resources away from community-prioritized supports. This realigns the power dynamic between federal agencies and autistic advocates, undermining years of work to center lived experience in policy. The operational consequence is a likely chilling effect on ethical, service-oriented research proposals within NIH grant cycles. For the community, it represents a tangible regression in the ‘nothing about us without us’ principle, with direct implications for safety and autonomy.
Date: Thu, 16 Apr 2026 15:19:02 +0000
URL: https://autisticadvocacy.org/2026/04/april-iacc-comments-2026/
AI Sentiment Score: Negative (71%)
AI Credibility Score: 10.0/10 — High
Scores and text generated by AI analysis of the source article indicated.Autism Awareness and Acceptance: Supporting Patients, Families, and Communities – UF Health Jacksonville (Ufhealthjax)
Summary: UF Health Jacksonville’s April 2026 statement frames Autism Awareness Month as a call for acceptance and systemic adaptation within healthcare. It emphasizes moving beyond a purely medical lens to focus on individualized, respectful care that accommodates sensory and communication needs. The piece positions healthcare institutions as central to creating inclusive environments through small, practical adjustments in clinical practice.
Why it matters: This signals a maturation of institutional neurodiversity discourse from awareness to operational integration, with direct implications for patient experience, clinical protocols, and liability.
Context: Major healthcare systems are increasingly publishing formal position statements on neurodiversity, reflecting both community advocacy pressure and a recognition of autism as a core demographic in patient populations.
"One of the most important messages of Autism Awareness Month is that autism is not something to be viewed only through a medical lens. While diagnosis and intervention can be important, so can acceptance, dignity, and inclusion." — UFHEALTHJAX
Commentary: The statement’s pivot from ‘awareness’ to ‘acceptance’ is a tactical shift, aligning with community-led advocacy and subtly pressuring peer institutions to follow suit. Its focus on environmental adjustments—lighting, noise, communication pace—translates abstract inclusion goals into actionable, low-cost clinical modifications that reduce sensory overload and mitigate litigation risk from inadequate care. By explicitly naming staff training and ‘everyday actions,’ it codifies a new standard of operational due diligence for large healthcare providers.
Date: April 14, 2026 12:00 AM ET
URL: https://ufhealthjax.org/stories/2026/autism-awareness-and-acceptance-supporting-patients-families-and-communities
AI Sentiment Score: Negative (80%)
AI Credibility Score: 7.0/10 — Medium
Scores and text generated by AI analysis of the source article indicated.Post ID: f0dad7a9